Ruti Aga's Six-Year Ban: A Forged Prescription, a Misclassified Drug, and a File Nobody Read to the End

A clinic that did not exist. A piece of paper signed by a 'doctor' who was a member of the athlete's own family. And an old prescription pad that the clinic, when asked, flatly disowned. The Athletics Integrity Unit's statement, released on Thursday, stands its entire case on those three sentences. Six years for Ethiopian marathoner Ruti Aga, counted from 10 September. Two years for the presence of a prohibited substance, four years for submitting forged documentation in its defence. A sample collected after she won a half marathon in China in March. A paper trail that turned a two-year absence into a career ending. The raw sheet had two stories. I followed the one with a receipt, and the receipt here belongs to the forged prescription — the race time appears in no document at all. Start with the part the source does not contain. No mark, no split, no field strength, no venue for that March half marathon is disclosed. Only that she won it. Twenty-two years of keeping start lists and result sheets in the same folder teaches one thing: 'won' is not a performance datum, it is a status. The day I watched Neeraj Chopra throw 85.23m at the 2026 Asian Championships in Bhubaneswar, I spent the following month building a spreadsheet of every Indian javelin mark from 2026 to 2026, because one meet's data is not a trend. Here the situation is reversed: the meet exists, the data does not. So I will not judge the performance. The only figure on offer is the sanction, and it carries enough on its own. Aga is 32. My own records carry her name against second place at Berlin 2026 (around 2:18:34) and the win at Tokyo 2026 (around 2:20:40); both figures come from my archive and need checking against the official result sheet, so treat them as pending verification. What the source itself confirms is three second-place finishes at World Marathon Majors. That is an elite profile, and I will state it plainly before I place the asterisk: a 2:18 to 2:20 marathoner with one Major title and three Major silvers is exceptional even inside Ethiopia's women's marathon pool. Which is also the pool's strength. Remove a 2:18 runner from Ethiopian selection and the team's depth does not move by a millimetre. That fact matters later. Now the part that is the actual news and that most reports got wrong. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA Prohibited List, and the decisive condition of S9 is that it is prohibited in-competition only, by injection, oral or rectal route. A therapeutic knee injection given out-of-competition is entirely legal. It becomes a violation only when residue is present in a sample taken in-competition. I trust the archive more than the highlight reel, especially when money and careers are at stake, and the archive says this case was always going to be fought on route and timing, not on drug class. Calling it a steroid placed the case in a category it does not belong to, and that error is what makes six years sound proportionate to a serious physical advantage. In endurance sport, glucocorticoids have no established performance benefit. This is a drug for pain and inflammation. Six years here is not a steroid sentence. It is a paperwork sentence. From that, the point the statement does not spell out. Aga had a legitimate defence available. Knee treatment is standard sports medicine in distance runners; intra-articular or peri-articular methylprednisolone is not exotic. With genuine medical records, a documented injection date, and a demonstrated washout period before competition, the presence charge could have been argued at the no-fault or no-significant-fault end. That is not a theory, it is the rule. She did not take that route. She had a prescription manufactured. And a prescription gets manufactured only when the real documents are missing. That is the hardest and cleanest reading of this file. The verification of that prescription failed in three separate places. The clinic named on it did not exist. The person who signed it was a family member with no medical registration. And the explanation offered for the pad — one left over from a former workplace — was rejected outright by the clinic it was attributed to. Three independent verification failures. For a reporter those are three checkpoints. For an athlete they describe one condition: no credentialed team physician anywhere in the chain. This is where I have to check my own habit. An anti-doping file feels like a complete story because it closes. What the file does not contain is also a finding. The statement nowhere says whether her agent or management was investigated. Only the family member is named. That silence is the largest unanswered question in the case, and it belongs to the AIU, not to the athlete. The arithmetic is plain and it carries the most information. Two years for the presence violation, the standard sanction for a Specified Substance where intent is not proven. Four years for tampering, the Code's standard penalty. Total six. Two conclusions follow. The panel declined the no-significant-fault mitigation that would have cut the presence period. And it treated the tampering as fully culpable, which produces an oddity: forged documents are themselves circumstantial evidence of concealment, yet they did not aggravate the presence sanction — they added four years on a separate limb. Counting the ban from 10 September is procedure, not leniency; provisional suspension time counts against the total. The athlete gains nothing in real terms. Then the part nobody covered, which is what made this explosive. The four-year tampering sanction does not rest on the document alone. It rests on an interview — on statements made under questioning. Language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring point of contention. I am not claiming translation failed here. I am noting that the file cites an interview and does not record its conditions. When this reaches an appeal, that is the first silence a lawyer will open. At the root of the case is a knee, and the knee is not incidental. Chronic knee pathology is the most common load-bearing failure in marathoners. An injured athlete faces two routes: document the treatment and return properly, or mask the pain and race, because the appearance-fee cheque is tied to the start line. A glucocorticoid is the cheapest, most available tool for the second route. The prescription came after that decision, not before it. It is an individual lapse rooted in a medical-governance gap that serves entire East African road-racing entourages at once. Because the real question is not where the drug came from. It is where the money comes from. Indian track and field runs on sports-quota jobs at Railways, Services, state police and PSUs; when I write about the economics of Indian athletics I look at the payslip before the podium. Ethiopia's equation is different. A marathoner's income is dominated by appearance fees, and the thickest layer of that income is the Chinese label-race circuit. That is where two economies now collide: the race that pays the fee, and the agency that collects the sample at the same race. The AIU's highest-yield testing ground is precisely the races that pay the most, because that is where the deepest elite fields assemble. Empty stadiums do not empty the ledger; the cost simply moves, and here it has moved out of the athlete's career and into the handful of races that hold the world's attention for three hours. So the easy reading — AIU rigour, deterrence delivered — is also the wrong one. Six years for a substance with no proven endurance benefit is not evidence of how strong the testing system is. It is evidence of where enforcement is cheap. Documents are cheap: a clinic's existence is settled by one phone call, a registration by one email. Chasing a blood passport takes five years. Sanctions arrive fastest exactly where the paperwork is thinnest, and that produces the appearance of severity regardless of the seriousness of the offence. Reports that called this a steroid ban erased the distinction and left a door open for every future minor lapse to be sentenced as a major one. A second point lives in the record's absences. The statement does not state the disqualification scope. Standard AIU practice voids the result from the competition where the sample was collected — the March race in China, its prize money, and the ranking points accrued there. The statement does not say so explicitly, and when a document is not explicit I do not assume it. What is explicit is that the violation attaches to that March race, and earlier results, including the 2026 Tokyo title, are not automatically annulled absent a finding of earlier use. That gap is enormous. On one side sits a six-year ban. On the other, a title that stays in the book. Which is also where the forward view sits. A six-year ban at 32 puts any return at roughly 38. Inside Ethiopia's women's marathon depth, a 38-year-old with a doping record is an administrative impossibility — not a prediction, just a reading of how that pool is built. Commercially the name is now uninvestable in a sport where distance-running sponsorship is already thin. What survives is the record: the Tokyo title, three Major silvers, a runner who was among the fastest of her generation. I do not discard the record and I do not discard the sanction. Both sit in the same file, and holding both at once is the job. Before I call it culture, I want to see who kept the receipts. Here no receipts were kept; a prescription was manufactured. Two things to watch in the next three weeks: whether an appeal is filed at CAS, and whether the reasoned decision publishes the technical grid on route and timing that this entire case rests on. If that grid never appears, the next forged prescription will come out of the same training cluster, because the tool is still sitting there. The real test is not the sentence. It is the appeal date and the federation's silence.